Prof. Dr. Richard P. Baum: Pioneer of Radiomolecular Precision Oncology
A Visionary in Theranostics and Nuclear Medicine
Prof. Dr. Richard P. Baum is a globally recognized nuclear medicine physician and one of the foremost pioneers in theranostics — the integration of molecular imaging and therapy, also known as radiomolecular precision oncology.
As Nuclear Medicine Physician at CURANOSTICUM Wiesbaden-Frankfurt, President of the ICPO Academy for Theranostics, and Chairman of the ICPO Foundation Scientific Advisory Board, Prof. Baum has dedicated his career to advancing radioligand therapy (RLT) for cancers such as prostate carcinoma and neuroendocrine tumors (NETs).
With nearly four decades of clinical experience, he has shaped the field with groundbreaking first-in-human studies, including the world’s first 177Lu‑PSMA therapy for prostate cancer in 2013, later advancing to TANDEM‑PRLT that combined 177Lu and 225Ac‑PSMA.
His guiding vision has always been clear: to combine cutting-edge radiomolecular techniques with patient-centered care, setting new international standards in nuclear medicine.
Clinical Breakthroughs and Global Impact
Over the course of his career, Prof. Baum and his team have treated more than 2,000 neuroendocrine tumor patients, performing over 7,000 peptide receptor radionuclide therapy (PRRT) applications. These therapies harness the theranostic principle: using advanced PET/CT molecular imaging to identify tumor cells and then targeting them with precision radiopharmaceuticals that deliver alpha or beta radiation directly to cancer cells while sparing healthy tissue.
This innovative approach has proven especially effective for patients with advanced prostate cancer and neuroendocrine tumors, often when other treatment options had been exhausted. The results are not only longer survival but also an improved quality of life, with significantly fewer side effects compared to conventional therapies.
Prof. Baum’s expertise extends beyond the clinic. He is an acclaimed researcher and educator, with hundreds of peer-reviewed publications, prestigious guest professorships at institutions including Michigan State University (USA) and Peking University Cancer Hospital (China), and leadership roles in major international organizations. He also chaired the first six Theranostics World Congresses, solidifying his influence as a global thought leader in theranostics.
Awards, Recognition, and Continuing Leadership
Prof. Baum’s pioneering work has earned him numerous awards and international recognition. Notably, he received the Mallinckrodt Award (1990), the GLORINET Award (2014) from the NET Patient Support Group in Germany, and the Saul Hertz Award (2019) from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), one of the highest honors in nuclear medicine therapy.
In addition, FOCUS Gesundheit has ranked him among Germany’s Top Physicians 2024, a testament to his continued leadership in nuclear medicine and radioligand therapy.
Today, as he continues his work at CURANOSTICUM Wiesbaden-Frankfurt, Prof. Baum remains dedicated to advancing radiopharmaceutical development, expanding access to radioligand therapies, and training the next generation of nuclear medicine specialists. His legacy continues to shape the future of theranostics and radiomolecular precision oncology, offering hope to thousands of cancer patients worldwide.